Crescendo Biologics expands Takeda collaboration 10th December 2020 Cambridge, UK-based Crescendo Biologics will expand its discovery and development collaboration with Japanese pharma company Takeda, which is focused on building Humabody-based therapeutics against undisclosed targets. The expanded collaboration comes following Crescendo’s achievement of its sixth technical milestone within the original collaboration agreement. The expansion will enable Takeda to access a range of Crescendo’s half-life extension Humabodies for use with its two Humabody programmes, licensed in November 2018 and July 2019. Crescendo added in a statement that it has successfully delivered novel oncology targeted Humabody lead molecules using its in-house discovery process. The UK firm describes its Humabody products as ‘a novel class of small, robust and potent protein therapeutics based on fully human VH domain building blocks’.